Page last updated: 2024-08-21

3-hydroxyflavone and Bone Neoplasms

3-hydroxyflavone has been researched along with Bone Neoplasms in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's2 (33.33)2.80

Authors

AuthorsStudies
Bharath, BM; Fu, CY; Huang, CY; Kuo, WW; Lay, IS; Shibu, MA; Tseng, YS; Wang, TF; Yang, JJ; Yeh, YL1
Chen, PN; Cheng, FY; Chiu, PC; Chu, SC; Hsieh, YH; Hsieh, YS; Lin, CY; Lu, KH1
Chou, CH; Hsieh, YH; Lin, CW; Lu, KH; Yang, JS; Yang, SF1
Almeida, L; Coutinho, L; Fernandes, E; Ferreira de Oliveira, JMP; Oliveira, H; Pacheco, AR; Pinho, S; Santos, C1
Chen, MC; Fu, CY; Huang, CY; Lin, YM; Tseng, YS; Viswanadha, VP; Wang, G; Yang, JJ; Zhou, Z1
Jia, Q; Kang, T; Lu, J; Shen, J; Song, G; Tang, Q; Wang, J; Wang, Y; Wu, MS; Wu, Y; Xie, XB; Yin, JQ; Zhao, Z; Zou, C1

Other Studies

6 other study(ies) available for 3-hydroxyflavone and Bone Neoplasms

ArticleYear
Selective Activation of ZAK β Expression by 3-Hydroxy-2-Phenylchromone Inhibits Human Osteosarcoma Cells and Triggers Apoptosis via JNK Activation.
    International journal of molecular sciences, 2020, May-09, Volume: 21, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Caspase 3; Cell Line, Tumor; Enzyme Activation; Flavonoids; Gain of Function Mutation; Humans; Loss of Function Mutation; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; Membrane Potential, Mitochondrial; Osteosarcoma; Protein Isoforms; Signal Transduction; Up-Regulation

2020
3-Hydroxyflavone inhibits human osteosarcoma U2OS and 143B cells metastasis by affecting EMT and repressing u-PA/MMP-2 via FAK-Src to MEK/ERK and RhoA/MLC2 pathways and reduces 143B tumor growth in vivo.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2016, Volume: 97

    Topics: Adolescent; Animals; Apoptosis; Biomarkers, Tumor; Blotting, Western; Bone Neoplasms; Cardiac Myosins; Cell Adhesion; Cell Movement; Cell Proliferation; Child; Epithelial-Mesenchymal Transition; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Focal Adhesion Protein-Tyrosine Kinases; Humans; Immunoenzyme Techniques; MAP Kinase Kinase 1; Matrix Metalloproteinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Myosin Light Chains; Osteosarcoma; rhoA GTP-Binding Protein; Signal Transduction; src-Family Kinases; Tumor Cells, Cultured; Urokinase-Type Plasminogen Activator; Xenograft Model Antitumor Assays

2016
Dihydromyricetin suppresses cell metastasis in human osteosarcoma through SP-1- and NF-κB-modulated urokinase plasminogen activator inhibition.
    Phytomedicine : international journal of phytotherapy and phytopharmacology, 2021, Volume: 90

    Topics: Bone Neoplasms; Cell Line, Tumor; Cell Movement; Flavonols; Humans; Neoplasm Invasiveness; Neoplasm Metastasis; NF-kappa B; Osteosarcoma; Sp1 Transcription Factor; Urokinase-Type Plasminogen Activator

2021
Combination of etoposide and fisetin results in anti-cancer efficiency against osteosarcoma cell models.
    Archives of toxicology, 2018, Volume: 92, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin B1; Cyclin E; Etoposide; Flavonoids; Flavonols; Gene Expression Regulation, Neoplastic; Humans; Oncogene Proteins; Osteosarcoma; Tumor Stem Cell Assay

2018
Fisetin activates Hippo pathway and JNK/ERK/AP-1 signaling to inhibit proliferation and induce apoptosis of human osteosarcoma cells via ZAK overexpression.
    Environmental toxicology, 2019, Volume: 34, Issue:8

    Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Flavonols; Hippo Signaling Pathway; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Osteosarcoma; Protein Kinases; Protein Serine-Threonine Kinases; Signal Transduction; Transcription Factor AP-1; Tumor Suppressor Proteins

2019
Dihydromyricetin activates AMP-activated protein kinase and P38(MAPK) exerting antitumor potential in osteosarcoma.
    Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:9

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Flavonols; Fluorescent Antibody Technique; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Real-Time Polymerase Chain Reaction; Signal Transduction; Xenograft Model Antitumor Assays

2014